entertainment -WSS

entertainment

author：comprehensive 2025-09-30 16:23:10 - browse：7884

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Weight loss drugs should be covered by insurers, AMA says

explore

WSS

Healthy food access boosts outcomes in two studies

Study suggests Covid rebound is far more common with Paxlovid than without

UnitedHealth wins $3.3 billion takeover of Amedisys

Study suggests Covid rebound is far more common with Paxlovid than without

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Brazil's Jair Bolsonaro is barred from running for office until 2030

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Ohio still needs to do more to protect the right to abortion

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Sports medicine is finally prioritizing gender equality

UnitedHealth wins $3.3 billion takeover of Amedisys

Alkermes shareholders re

Today's health inequities arise from racist U.S. history, say experts

Novavax promises a turnaround & Lilly roils the obesity market

Here's how to stay safe from wildfire smoke amid reduced air quality

entertainment

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

What health policies could hitch a ride on a spending bill?

Synthetic human embryos? Researchers say term is overblown

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

entertainment

explore

hotspot

hotspot